

MEETING MINUTES

Consortium for Medical Marijuana Clinical Outcomes Research: BOARD MEETING

Friday, Sept 3rd, 2021 at 1:00 pm

Remote Connection via Zoom

Board Members Present:

William Anderson, Chair
Martha Rosenthal, Vice-Chair
Roger Fillingim
Jacqueline Sagen
Ximena Levy
Charles Weatherford
Max Orezza
Timothy Gilbertson

Board Members Absent:

Eric Holmes

Attendees:

Almut Winterstein, Consortium Director
Robert Cook, Consortium Associate Director
Joshua Brown
Amie Goodin
Anna Shavers
Jeevan Jyot
Sebastian Jugl
Ruba Sajdeya
Golnoosh Alipour-Haris

OMMU

Dr. Michelle Chandrasekhar

Opening Remarks

Dr. William Anderson of Florida International University (FIU) and Chair of the Board, called the meeting to order at 1:00pm. He welcomed all board members and thanked them for attending. He requested Dr. Jacqueline Sagen from University of Miami to introduce herself as the new Board Member. Dr. Chandrasekhar from OMMU was also welcomed to the meeting and she commented that she was happy to be present.

Bylaws amendment and COI disclosures

Dr. Anderson reminded the board members to complete their conflict disclosure forms. Two bylaw amendments were introduced to enable Zoom meetings to be acceptable as in-person attendance and have one in-person meeting annually. Dr. Rosenthal suggested removing the in-person requirement unless mandated by the Florida Statute and Dr. Orezza agreed. Dr. Winterstein checked the statute which did not list an in-person meeting requirement for the board. The bylaw language was appropriately edited and amended. Dr. Anderson called the motion for approval of the bylaws amendment and Dr. Rosenthal seconded it. All present voted in favor and no member abstained from voting. The motion to amend the bylaws was passed.

Overview of Research Plan 2021-22

Dr. Almut Winterstein, Director of the Consortium welcomed the board members to review and approve the research agenda for the third year of Consortium. Dr. Winterstein presented the 2021-22 research program proposal along with Dr. Amie Goodin and Dr. Robert Cook. Dr. Winterstein provided a recap of the originally established 5 Consortium pillars, under which the Consortium research program operates and shared the accomplishments under each. The Grants program has completed the 2019 cycle and will complete the 2020 cycle by December 2021. The Consortium board approved the awards for the 2021 cycle in July, funding

over budget at \$709,846. Research outcomes of first awardees will be showcased this year and a new grants cycle will be launched by December end. For MEMORY progress was reported with the IRB at UF approved, along with DUAs signed for obtaining vital statistics and Medicaid claims data. Three DUA agreements with OMMU are currently pending and additional communication regarding finalization is ongoing. The Clinical core has successfully enrolled participants both for CARMMA and the contact registry and is launching Medical Marijuana and Me (M³), a prospective cohort. For the Outreach pillar, Dr. Amie Goodin shared plans for the next CCORC conference to be held on May 19th-20th, 2022 in Orlando, which will be held in-person, with hybrid options. Representation from the member institutions was sought for the Scientific Program Committee. Dr. Winterstein continued stating that additional Outreach activities, including launching a new Consortium research spotlight series, press releases, publication of the Consortium newsletter, maintenance of an active website, and participation at conferences, will be achieved. The Evidence core will lead the scientific program for CCORC, publish new evidence-in-context articles, patient infoshets and update the research priorities. Finally, Dr. Cook presented the strategic goals for Medical Marijuana and Me (M³), including research questions that the M³ survey hopes to address and the timeline of activities.

Dr. Ximena Levy congratulated the team for presenting the research program, and commented that this will help address the scarcity of reliable data and knowledge, as regards marijuana clinical outcomes.

Consortium's funding update & Budget Proposal FY22

Dr. Winterstein, Director of the Consortium shared that the state has funded the Consortium for \$1.5M and presented the proposed budget for FY22 for \$1,750,208 with plans to use residual carry forward funds from FY21, to cover all the expenses associated with the proposed research plan.

Dr. Anderson thanked the UF team for their work and offered his appreciation.

Vote on Approval for FY22 Budget

Dr. William Anderson, initiated the motion to approve the proposed budget and Dr. Levy seconded the motion. Dr. Rosenthal left the meeting early but conveyed her approval for the budget via Zoom meeting message. All present approved the motion and no one abstained. The motion for approval of the FY22 budget was passed.

Public Comments

The Chair invited comments from the public and none were submitted.

Closing Remarks

Dr. Anderson reminded the board that the next meeting will be coming up after Thanksgiving to finalize the RFP for the 2022 Grants Program and to also be on the lookout for an email as regards nominating representatives for the CCORC Scientific Program Committee.

Adjournment

Dr. Anderson moved the motion to adjourn the meeting and was seconded by Dr. Fillingim and all present agreed. No one abstained. The meeting was adjourned at 2:13 PM.